Targeted beta therapy of prostate cancer with <sup>177</sup>Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).

EJNMMI Res · 2020 · PMC7206480 · PMID 32382920

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

Mice that received 3 MBq of [ 177 Lu]Lu-DOTA-Miltuximab® showed a trend towards prolonged survival versus control, but did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.